We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
ERS Genomics Licenses CRISPR Gene Editing Technology to Bioneer to Further Advance Preclinical Disease Modelling
Product News

ERS Genomics Licenses CRISPR Gene Editing Technology to Bioneer to Further Advance Preclinical Disease Modelling

ERS Genomics Licenses CRISPR Gene Editing Technology to Bioneer to Further Advance Preclinical Disease Modelling
Product News

ERS Genomics Licenses CRISPR Gene Editing Technology to Bioneer to Further Advance Preclinical Disease Modelling


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "ERS Genomics Licenses CRISPR Gene Editing Technology to Bioneer to Further Advance Preclinical Disease Modelling"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

ERS Genomics Limited and Bioneer A/S today announced the signing of a license agreement providing Bioneer access to CRISPR/Cas9 genome editing technology intellectual property. Bioneer, a Denmark based life science research and technology provider, will utilize CRISPR/Cas9 technology to generate a range of innovative human cell based disease models.

Under the terms of the license, Bioneer is able to generate and commercialize CRISPR-edited cell based models, broadening its core capabilities and expanding on Bioneer's expertise in biomedical research support.

Eric Rhodes, CEO of ERS Genomics, said: “Bioneer has proven expertise in a broad array of biomedical fields. Adding CRISPR/Cas9 to their toolbox ensures they remain on the leading edge of technology. We are very pleased that Bioneer chose to expand on its service offering by licensing CRISPR/Cas9 technology through ERS Genomics."

“This cutting-edge technology will complement Bioneer’s competences in advanced preclinical disease modelling.” stated Lars H. Pedersen, CEO of Bioneer. Christian Clausen, CSO of Bioneer continues: “Bioneer is working with both industry and academia to solve complex disease relevant questions by using advanced disease modelling. The CRISPR/Cas9 tools will enable clients and collaborators to precisely tailor their preclinical modelling strategies to their specific needs for predictive in vitro models.”
Advertisement